F-Star lands on NASDAQ sooner than expected via reverse merger

At the year’s start F-Star Therapeutics’ plan was to ride out the expected volatility of the U.S. election year and seek a public listing in 2021. That changed when Spring Bank called with an opportunity for the immuno-oncology company to gain a NASDAQ listing via a reverse merger.

On Thursday the companies announced an all-stock deal that will result in F-Star Therapeutics Ltd. becoming publicly listed with its shareholders owning about 62% of the combined company. Investors of Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) will own the rest, subject to final cash figures for both companies...